In re Carroll
This text of 586 B.R. 775 (In re Carroll) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, E.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
Ronald H. Sargis, Judge United States Bankruptcy Judge
Patricia Carroll, a co-debtor in this case ("Debtor"), filed her Motion for the court to "Determine Product Liability Settlement Is Not Property Of The Bankruptcy Estate." Motion, Dckt. 75.1 Debtor has filed the declarations of her attorney (Dckt. 77) and herself (Dckt. 78) in support of the Motion. In addition, Debtor has filed as documentary evidence the FDA July 2011 Urogynecologic Surgical Mesh Update in support of the Motion. Dckt. 79.
Michael McGranahan, the Chapter 7 Trustee ("Trustee"), filed his Opposition to the Motion. Dckt. 87. Additionally, three declarations were filed in opposition to the Motion: Declaration of Trustee's Counsel (Dckt. 88), Declaration of Trustee (Dckt. 89), and Declaration of Counsel for Class Action Settlement (Dckt. 90). The Trustee filed documentary evidence opposing the Motion and asserting the interests of the bankruptcy estate in this case ("Bankruptcy Estate") in the claims, which included the Debtor's Schedules, Class Action Settlement documents, and the FDA July 2011 Urogynecologic Surgical Mesh Update (same as submitted by Debtor). Dckt. 91.
Debtor responded, presenting rebuttal evidence in the form of a second Declaration by Debtor's counsel. Dckt. 96. Debtor submitted additional rebuttal documentary evidence consisting of a May 9, 2017 Decision of the District Court for the Eastern District of New York and a second copy of the FDA July 2011 Urogynecologic Surgical *777Mesh Update (authenticated by Debtor's counsel's supplemental declaration). Dckt. 97.
Upon review of the evidence presented and determination of applicable law, this court determines that the rights and claims which are the subject of the Class Action Settlement, and the Class Action Settlement Proceeds thereof, are property of the Bankruptcy Estate in this case.
CORE MATTER PROCEEDING AND PROPER ADJUDICATION PROCEDURE
The Motion presents the court with a core matter proceeding-determination of property of the bankruptcy estate pursuant to
At the February 1, 2018 hearing, the court addressed this procedural issue with the parties. At said hearing, both Parties confirmed on the record that they consented to the determination of their clients' respective interests in the property at issue in this contested matter, waiving the right to have those interests adjudicated in an adversary proceeding. Such waiver by the parties, electing to proceed by contested matter proceeding is permissible. Feld v. Zale Corp. (In re Zale Corp.) ,
The court concurs with the election by the Parties to proceed by contested matter. Both are represented by experienced, knowledgeable counsel. No prejudice exists for either Party, nor the court, out of the election.
ISSUES PRESENTED AND POSITIONS ADVANCED BY THE PARTIES
The Debtor requests that this court determine that the product liability settlement proceeds, flowing from a transvaginal mesh patch implant (the "Device"), which claim is now listed on Amended Schedule B, are not property of the Bankruptcy Estate. The Class Action lawsuit (Debtor was not the class action plaintiff, but subsequently determined to be a class member) has resulted in the claims and rights at issue having a value of $240,000.00-the "Class Action Settlement Proceeds" distribution for Debtor's claim. Debtor has now claimed an exemption of $240,000.00 pursuant to California Code of Civil Procedure § 704.140 in the Class Action Settlement Proceeds on Amended Schedule C. Dckt. 54.
Debtor's bankruptcy case was filed on February 6, 2009, with Debtor receiving her discharge on May 19, 2009 (Dckt. 31). Debtor relates that she had a transvaginal mesh patch implanted on August 22, 2003 (five and one-half years prior to the bankruptcy case being filed), which resulted in subsequent medical issues, leading to *778Debtor pursuing her rights to the class action recovery in 2015. Dckt. 78.
Debtor argues that she did not "know" about any "legal claim" that was available to her until 2014, and as such, the claim was not "sufficiently rooted" in her prepetition past such that it would be an interest of the Bankruptcy Estate. Debtor argues that her claim did not accrue until 2014 when she learned of a United States Food and Drug Administration ("FDA") warning and when she subsequently that year learned about being able to sue the manufacturer of her transvaginal mesh patch.
Therefore, Debtor argues that the settlement proceeds are not part of the Bankruptcy Estate in this case and requests that the court issue an order holding the same.
Debtor's Authorities and Arguments
Debtor's legal basis for this argument begins with citing to Butner v. U.S. ,
Free access — add to your briefcase to read the full text and ask questions with AI
Ronald H. Sargis, Judge United States Bankruptcy Judge
Patricia Carroll, a co-debtor in this case ("Debtor"), filed her Motion for the court to "Determine Product Liability Settlement Is Not Property Of The Bankruptcy Estate." Motion, Dckt. 75.1 Debtor has filed the declarations of her attorney (Dckt. 77) and herself (Dckt. 78) in support of the Motion. In addition, Debtor has filed as documentary evidence the FDA July 2011 Urogynecologic Surgical Mesh Update in support of the Motion. Dckt. 79.
Michael McGranahan, the Chapter 7 Trustee ("Trustee"), filed his Opposition to the Motion. Dckt. 87. Additionally, three declarations were filed in opposition to the Motion: Declaration of Trustee's Counsel (Dckt. 88), Declaration of Trustee (Dckt. 89), and Declaration of Counsel for Class Action Settlement (Dckt. 90). The Trustee filed documentary evidence opposing the Motion and asserting the interests of the bankruptcy estate in this case ("Bankruptcy Estate") in the claims, which included the Debtor's Schedules, Class Action Settlement documents, and the FDA July 2011 Urogynecologic Surgical Mesh Update (same as submitted by Debtor). Dckt. 91.
Debtor responded, presenting rebuttal evidence in the form of a second Declaration by Debtor's counsel. Dckt. 96. Debtor submitted additional rebuttal documentary evidence consisting of a May 9, 2017 Decision of the District Court for the Eastern District of New York and a second copy of the FDA July 2011 Urogynecologic Surgical *777Mesh Update (authenticated by Debtor's counsel's supplemental declaration). Dckt. 97.
Upon review of the evidence presented and determination of applicable law, this court determines that the rights and claims which are the subject of the Class Action Settlement, and the Class Action Settlement Proceeds thereof, are property of the Bankruptcy Estate in this case.
CORE MATTER PROCEEDING AND PROPER ADJUDICATION PROCEDURE
The Motion presents the court with a core matter proceeding-determination of property of the bankruptcy estate pursuant to
At the February 1, 2018 hearing, the court addressed this procedural issue with the parties. At said hearing, both Parties confirmed on the record that they consented to the determination of their clients' respective interests in the property at issue in this contested matter, waiving the right to have those interests adjudicated in an adversary proceeding. Such waiver by the parties, electing to proceed by contested matter proceeding is permissible. Feld v. Zale Corp. (In re Zale Corp.) ,
The court concurs with the election by the Parties to proceed by contested matter. Both are represented by experienced, knowledgeable counsel. No prejudice exists for either Party, nor the court, out of the election.
ISSUES PRESENTED AND POSITIONS ADVANCED BY THE PARTIES
The Debtor requests that this court determine that the product liability settlement proceeds, flowing from a transvaginal mesh patch implant (the "Device"), which claim is now listed on Amended Schedule B, are not property of the Bankruptcy Estate. The Class Action lawsuit (Debtor was not the class action plaintiff, but subsequently determined to be a class member) has resulted in the claims and rights at issue having a value of $240,000.00-the "Class Action Settlement Proceeds" distribution for Debtor's claim. Debtor has now claimed an exemption of $240,000.00 pursuant to California Code of Civil Procedure § 704.140 in the Class Action Settlement Proceeds on Amended Schedule C. Dckt. 54.
Debtor's bankruptcy case was filed on February 6, 2009, with Debtor receiving her discharge on May 19, 2009 (Dckt. 31). Debtor relates that she had a transvaginal mesh patch implanted on August 22, 2003 (five and one-half years prior to the bankruptcy case being filed), which resulted in subsequent medical issues, leading to *778Debtor pursuing her rights to the class action recovery in 2015. Dckt. 78.
Debtor argues that she did not "know" about any "legal claim" that was available to her until 2014, and as such, the claim was not "sufficiently rooted" in her prepetition past such that it would be an interest of the Bankruptcy Estate. Debtor argues that her claim did not accrue until 2014 when she learned of a United States Food and Drug Administration ("FDA") warning and when she subsequently that year learned about being able to sue the manufacturer of her transvaginal mesh patch.
Therefore, Debtor argues that the settlement proceeds are not part of the Bankruptcy Estate in this case and requests that the court issue an order holding the same.
Debtor's Authorities and Arguments
Debtor's legal basis for this argument begins with citing to Butner v. U.S. ,
Focusing on the assertion that as of the commencement of the bankruptcy case no claim had "accrued" for Debtor, and therefore no claim could exist for purposes of
§ 312. Commencement of civil actions
Civil actions, without exception, can only be commenced within the periods prescribed in this title, after the cause of action shall have accrued, unless where, in special cases, a different limitation is prescribed by statute.
As addressed at the hearing, this is the general rule governing civil actions requiring them to be timely prosecuted. Debtor focuses on the use of the word "accrued" in this provision setting forth the general rule against the presenting of stale claims arising under California law.
Debtor's discussion continues, directing the court to the proposition that a cause of action does not accrue (for purposes of the running of the statute of limitations on bringing an action) until all of the elements of the claim exist. Debtor directs the court to Norgart v. Upjohn ,
In responding to the Trustee's Opposition, Debtor advances her case by pressing the Delayed Discovery Rule.4 Debtor argues *779that she did not become aware of the potential defective nature of the pelvic mesh device until 2014. Reply, Dckt. 94. Debtor argues that after consulting with an attorney in 2005 about the device, she was informed by that attorney that there was no factual or legal basis to believe that the mesh implant was defective at that time, meaning that she had no knowledge of a viable claim. Therefore, because Debtor asserts she did not know of a claim, then no claim could have existed when this case was filed because the running of the statute of limitations was tolled under the Delayed Discovery Rule.
Debtor agrees with the Chapter 7 Trustee's reading of In re Goldstein that the Bankruptcy Appellate Panel "found that if a claim could have been [brought], it has accrued." Debtor contends that no claim could have been brought because she did not know she had a claim when the bankruptcy case was filed. Debtor believes that it is the existence of the July 2011 FDA Update that caused her to "know" of a claim, thus the claim cannot exist before July 2011.
It appears that Debtor asserts an "all for me and nothing for you" position, contending that all of the claims and rights, from which the Class Action Settlement Proceeds flow, are either: (1) Debtor's post-petition property because Debtor asserts that she did not have "knowledge" of such rights or possible claim; or (2) Bankruptcy Estate Property if the claims existed prepetition. As presented by Debtor, the existence or non-existence of the claim, rights, and Class Action Settlement Proceeds turns on the Debtor's personal, non-legal, "knowledge" of the law and the existence of such existing, enforceable rights.
CHAPTER 7 TRUSTEE's OPPOSITION
Michael McGranahan (the "Chapter 7 Trustee") filed an opposition on January 17, 2018. Dckt. 86. The Chapter 7 Trustee alleges that determination of whether the settlement proceeds are property of the estate will depend on the date Debtor's claim accrued. Id. at 4:17-18.
The Chapter 7 Trustee concurs that determination of the interests in the claim is a matter of state law, not federal law. Id. at 4:18-19 (citing Goldstein v. Wells Fargo Bank, N.A. (In re Goldstein) ,
The Chapter 7 Trustee bases his contention that the claim "accrued" prepetition based on a number of dates and events disclosed by the Debtor:
A. August 22, 2003, mesh implantation;
B. October 8, 2003, excision of exposed section of mesh implant;
C. June 10, 2005, excision of pelvic foreign body and repair of implant; and
D. November 14, 2005, excision of mesh pieces and clips.
The Chapter 7 Trustee argues that Debtor knew or suspected that she had a claim around 2005 when she first consulted an attorney. See Exhibit to Amended Schedule B, Dckt. 54 (stating that "wife consulted an attorney regarding a possible claim" around 2005).
Thus, the Chapter 7 Trustee would appear to cede to Debtor that the only issue being presented to the court in determining the interests in the claim for the prepetition medical treatment with the Device *780is when it "accrues" for purposes of computing the (procedural) statute of limitations under California law.5
The Chapter 7 Trustee relies heavily on the Bankruptcy Appellate Panel's ruling in Goldstein v. Wells Fargo Bank, N.A. (In re Goldstein) , for a similar legal scenario about a legal claim becoming available post-petition based on prepetition facts. In that case, the Bankruptcy Appellate Panel rejected the debtor's contention that his claim did not accrue until post-petition when he learned certain facts. Instead, the Panel focused on California law holding that accrual happens "upon the occurrence of the last element essential for the cause of action."
The Chapter 7 Trustee argues that all of the necessary facts for Debtor's products liability claim arose between 2003 and 2005, prepetition. Therefore, any settlement proceeds from her products liability lawsuit are property of the Estate.
CHAPTER 7 TRUSTEE's OBJECTION TO EXHIBIT A
The Chapter 7 Trustee filed an Objection to Exhibit A on January 17, 2018. Dckt. 87. He argues that Exhibit A (FDA safety notice) has been introduced without any evidentiary basis and has not been properly authenticated in violation of Federal Rule of Evidence 901. Further, the Chapter 7 Trustee argues that Debtor is not a medical specialist or expert who can introduce the FDA safety notice as part of her expert opinion by Federal Rules of Evidence 702 through 706. He also argues that the document is hearsay under Federal Rule of Evidence 801 to which no exception applies.
In her Declaration, Debtor bases her testimony on personal, first-hand knowledge and does not present herself as an expert witness. Her Declaration contains one reference to the FDA safety notice filed as Exhibit A; Debtor states that "[i]n or about 2014 I learned that in July 2011 the FDA issued certain warning orders about the use of the mesh implant (See Exhibit 'A')." Dckt. 78 at 3:13.5-14.5. Debtor does not give any other reference to the exhibit, not even saying that she read it and learned about any defect. Instead, Debtor testifies that she learned about the mesh implant defect "when [she] was contacted by an attorney in 2014 about representing [her] regarding any potential claim [she] had." Id. at 3:14.5-15.5.
Debtor's statements are not in the form of authenticating evidence. She does not even state that she is the one who obtained a copy the FDA safety notice provided as an exhibit. She appears to allege that the statements within the report are true (hearsay), but her counsel does not present any argument in the Motion for a hearsay exception to apply. Even after the Chapter 7 Trustee filed his Objection, Debtor and her counsel have not responded. The court finds that Debtor's Exhibit A has not been properly authenticated in violation of Federal Rule of Evidence 901, and it contains hearsay statements that have not been presented under an exception to Federal Rule of Evidence 801. The court does not address the Exhibit's admissibility under Federal Rules of Evidence 702 through 706 because Debtor does not hold herself out as an expert witness.
*781The Objection to Exhibit A is sustained and Debtor's Exhibit A is not admitted into evidence.
However, the Trustee has submitted the same July 11, 2011 FDA Update on Safety and Effectiveness of Transvaginal Placement for Pelvic Organ Prolapse. Trustee's Exhibit A, Dckt. 91, pp. 38-52. This is the same document as Debtor's Exhibit A that is the subject of the above objection by the Trustee. Debtor's Exhibit A, Dckt. 79, pp. 2-16; resubmitted as Debtor's Exhibit B, Dckt. 97, pp. 10-24.
Debtor has not objected to the admission of Trustee's Exhibit A, the July 11, 2011 FDA Update on Safety and Effectiveness of Transvaginal Placement for Pelvic Organ Prolapse, and the July 11, 2011 FDA Update is admitted into evidence for the Trustee.
DISCUSSION
FDA Update
Both Parties direct the court to the July 11, 2011 FDA Update on Safety and Effectiveness of Transvaginal Placement for Pelvic Organ Prolapse (having been presented to the court three times by both Debtor and Chapter 7 Trustee). This 2011 FDA publication states that it is an Update of information previously communicated by the FDA. Title Page to FDA "Urogynecologic Surgical Mesh : Update on the Safety and Effectiveness of Transvaginal Placement for Pelvic Organ Prolapse." Chapter 7 Trustee's Exhibit A, Dckt. 91, pp. 38-52; and Debtor's Exhibit B, Dckt 97, pp. 10-24 (emphasis added). This Update begins with an Executive Summary which includes the following information:
I. EXECUTIVE SUMMARY
In October 2008 , the FDA issued a Public Health Notification (PHN) to inform clinicians and patients of adverse events related to urogynecologic use of surgical mesh , and to provide recommendations on how to mitigate risks and how to counsel patients. Following the PHN, the FDA continued to monitor the outcomes of urogynecologic use of surgical mesh. A search of the FDA's Manufacturer and User Device Experience (MAUDE) database from the last 3 years (January 1, 2008-December 31, 2010), identified 2,874 Medical Device Reports (MDRs) for urogynecologic surgical meshes, including reports of injury, death, and malfunctions. Among the 2,874 reports, 1,503 were associated with pelvic organ prolapse (POP) repairs, and 1,371 were associated with stress urinary incontinence (SUI) repairs.
The FDA also conducted a systematic review of the scientific literature to learn more about the safety and effectiveness of POP and SUI using surgical mesh. The FDA determined that (1) serious adverse events are NOT rare, contrary to what was stated in the 2008 PHN , and (2) transvaginally placed mesh in POP repair does NOT conclusively improve clinical outcomes over traditional non-mesh repair.
The FDA is providing this update to advise the public and the medical community of complications related to transvaginal POP repair with mesh. The FDA plans to convene an advisory panel meeting of outside experts in September 2011 to discuss these findings and the types of clinical studies necessary to better assess the risks and benefits of using mesh to treat POP and SUI. In addition FDA is considering regulatory changes that may improve our understanding of the safety and effectiveness of this device.
The FDA continues to evaluate the effects of using surgical mesh for the *782treatment of SUI and will report about that usage at a later date.
Neither the Debtor nor Trustee has provided the court with a copy of the 2008 public notice by the FDA.
The 2011 Update does tell us that it is updating information from an October 2008 FDA Public Health Notification to inform clinicians and patients of adverse events related to urogynecologic use of surgical mesh, and to provide recommendations on how to mitigate risks and how to counsel patients. Thus, as of 2008 the information was publicly available to both doctors and patients of the "adverse events" relating to the medical treatment with the Device that was performed on Debtor. The 2011 Update states that the prior treatment did cause serious medical events.
Confusion of Property of the Estate, the Obtaining of Rights, and the Commencement of the Running of the Statute of Limitations
Much argument between the parties exists over when the cause of action "accrues" for purposes of the computation of the California statute of limitations on filing a complaint to enforce the rights-as opposed to the real question, when do rights come into existence such that they become property of the bankruptcy estate as provided in
Congress does not qualify or limit a debtor's legal interest based on whether the debtor did or did not know that she had a legal interest (a cause of action) or whether state law tolls the running of the statute of limitations on bringing suit to enforce such interests based on Debtor not being aware of such interests. See, e.g. , In re Ross ,
Instead, Congress provides in
A legal interest that exists at the commencement of a case is one in which all of the elements for the cause of action are present. See, e.g. , Sierra Switchboard Co. v. Westinghouse Elec. Corp. ,
*783Claycomb v. Ulrich (In re Claycomb) ,
If a necessary element for the cause of action is missing at the commencement of the bankruptcy case, though, then the cause of action (and any proceeds from it) is not property of the estate. See Sikirica v. Harber (In re Harber) ,
A Debtor's Lack of Subjective Knowledge Of An Existing Claim Does Not Prevent It From Becoming Property of the Bankruptcy Estate
For Debtor's cause of action at issue to be property of the Bankruptcy Estate in this case, she must have had a products liability claim (whether she knew it or not) as of the commencement of this case. In California, a products liability action based on strict liability follows the general rule of the Third Restatement of Torts that "[o]ne engaged in the business of selling or otherwise distributing products who sells or distributes a defective product is subject to liability for harm to persons or property caused by the defect." 6 WITKIN, SUMMARY OF CAL. LAW (10th), Torts § 1430 (citing RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 1 (AM. LAW INST. 1998) ).
Similarly, the products liability action could be based on a negligence theory-the plaintiff does not need to elect for one theory over another. See Jiminez v. Sears, Roebuck & Co. ,
In her Declaration, Debtor states that she had a transvaginal mesh implanted on August 22, 2003. Dckt. 78 at 2:12-14.5. After that surgery, she "had considerable pain and anguish." Id. at 2:16. She underwent five additional prepetition surgeries "to remove and/or alleviate [the] symptoms" caused by the transvaginal mesh. Id. at 2:17-18. By Debtor's own statements, she was injured by a product. If that injury was caused because the device was defective, then it occurred during the procedures "in the years 2003, 2004, and 2005." Id. at 2:18. If the defects were in the product, and if the product had not been altered since leaving manufacture's control, then the defects existed when they left the manufacture's control prior to 2003.
All of the events were in place during the mid-2000s for Debtor to bring a cause of action based on products liability. Debtor had a prepetition claim, whether she realized it or whether she did not. Her asserted lack of knowledge did not stop the legal interest in a products liability lawsuit from existing.
*784Review of Decision in Mendelsohn and Other Authorities
Debtor directs the court to the decision of the District Court in Mendelsohn v. Ross (In re Ross) ,
Given that Debtor, in large part, hangs her hat on Mendelsohn and an assertion that the New York Court concluded that the issuance of the 2011 FDA Update was determinative, this court detours slightly to consider such contention and explain why the analysis in Mendelsohn is not persuasively determinative.6 The facts and applicable law as stated by the District Court in Mendelsohn are summarized as follows.
Ross, the debtor in Mendelsohn , filed her bankruptcy case on November 23, 2004. She did not schedule any interest in a products liability claim or personal injury claim on her bankruptcy schedules. The bankruptcy court approved a settlement between Ross and the trustee for the estate's asserted rights in certain real property. This allowed for a 23% dividend paid to creditors with general unsecured claims in the bankruptcy case. Ross' bankruptcy case was closed on August 2, 2006.
In 2015, the trustee in Ross' bankruptcy case had the case reopened, asserting the right to administer an undisclosed asset-a products liability claim for personal injury caused by the prepetition medical procedure involving the implanting of a defective medical device (the same Device as in the Motion now before the court). Ross asserted that she had the procedure in 1999, was unaware of any claim when she filed bankruptcy in 2006, and did not learn of a possible claim until after the 2011 FDA Update was issued. Thus, Ross asserted that no claim existed to be property of the bankruptcy estate when her bankruptcy case was filed in 2005. However, as stated in the Mendelsohn Decision, no such claims existed to become property of the estate. It was not merely that Ross did not know of the existing claims when that bankruptcy case was filed.
The Mendelsohn decision begins with the assertion that, as a matter of federal law, the court must determine whether such claim has "accrued"; citing Osborne v. Tulis ,
*785Our analysis begins with11 U.S.C. § 541 (a) (1), which defines the bankruptcy estate as including "all legal or equitable interests of the debtor in property as of the commencement of the case." "It would be hard to imagine language that would be more encompassing" than this broad definition. 4 Collier on Bankruptcy P 541.01 (15th ed. 2001). "[E]very conceivable interest of the debtor, future, nonpossessory, contingent, speculative, and derivative, is within the reach of § 541. " In re Yonikus ,996 F.2d 866 , 869 (7th Cir. 1993). Contractual rights clearly fall within the reach of this section, see, e.g., Cohen v. Drexel Burnham Lambert Group, Inc. (In re Drexel Burnham Lambert Group, Inc.) ,138 B.R. 687 , 701 (Bankr. S.D. N.Y. 1992), as do causes of action owned by the debtor or arising from property of the estate, see Seward v. Devine ,888 F.2d 957 , 963 (2d Cir. 1989).
Id. at 122 (emphasis added).
The Second Circuit goes further in Chartschlaa , providing a discussion of when even postpetition "acquired" property will be property of the bankruptcy estate if "it is 'sufficiently rooted in the pre-bankruptcy past.' " Id.
Applying these principles in Osborne , the Second Circuit affirmed a decision that the claim for malpractice by an attorney who failed to obtain an extension of the automatic stay in that debtor's prior bankruptcy case was property of the of the bankruptcy estate in that debtor's subsequent bankruptcy case, notwithstanding that the actual sale of the home (and loss) did not occur until three months after the filing of the subsequent bankruptcy case. As stated by the court in Osborne , based on New York State Law, the claims for the malpractice had "accrued" (using that term to describe the elements necessary to create the rights, not when one begins computing the statute of limitations) when the legal malpractice mistake became irrevocable, not when the first foreseeable consequence occurred in the future. Nowhere in the Osborne decision are the words "statute of limitations" used or discussed.
Moving back to Mendelsohn , the District Court cites Aetna Life & Casualty Co. v. Nelson ,
The Statute of Limitations begins to run once a cause of action accrues ( CPLR 203 [a] ), that is, when all of the facts necessary to the cause of action have occurred so that the party would be entitled to obtain relief in court (1 Weinstein-Korn-Miller, NY Civ Prac para. 201.02, at 2-9; City of New York v. State of New York ,40 N.Y.2d 659 , 668 [389 N.Y.S.2d 332 ,357 N.E.2d 988 ] ). Thus the question is not when the lien first attached, or when the insurer could have established the lien (cf. Biette v. Baxter ,57 N.Y.2d 698 [454 N.Y.S.2d 535 ,440 N.E.2d 534 ] ) but when the insurance company first had the opportunity to enforce or foreclose the lien and actually recover from the defendants the amounts it had previously paid them as first-party benefits under the No-Fault Law.
*786Id. at 174,
The court in Mendelsohn then relies upon the agreement of the bankruptcy trustee and Ross that "the parties do not dispute that the claim [of Ross] did not accrue prepetition because appellee [Ross] did not sustain an injury , as required in product liability claims." Mendelsohn v. Ross ,
As the Bankruptcy Court noted, this case presents a somewhat novel question in this Circuit: in a situation in which a debtor receives proceeds of a settlement where, because the underlying facts do not establish all the elements of the potential legal basis for suit , she may not ever be able to successfully bring suit, ....
a. " the underlying facts do not establish all the elements of the potential legal basis for suit;"
b. Ross "may not ever be able to successfully bring suit;"
c. " it was not inevitable that debtor's claim in the instant case would have ever accrued [stating that until there was an injury, there could be no claim];"
d. the bankruptcy court assumed that there was no injury ; and
e. Ross' "past did not create an interest that manifested itself in the settlement agreement."
In Mendelsohn , the real point of determination is the agreement between the trustee and Ross that there were no prepetition injuries upon which a claim could be based.
*787In Mendelsohn , Ross was electing to settle her possible future claims for the post-petition payment. While the Device was implanted prepetition, there were no prepetition injuries upon which a claim could be based under New York Law. That necessary element of any potential tort claim missing, there were no claims or rights for the bankruptcy estate upon the commencement of the bankruptcy case by Ross.
Additional Authorities For Determining Property of the Bankruptcy Estate
In considering the proper application of the principles enunciated by the Supreme Court in Segal and the broad scope of
Thus, the scope of 541 is broad: that section brings into the estate all of the debtor's legal and equitable interests 'wherever located and by whomever held.' 541(a)(1). However, the Code also provides a temporal limitation: property of the estate is determined at 'the commencement of the case.'Id. The case is commenced, and the estate created, when the bankruptcy petition is filed. See [State Farm Life Ins. Co. v. Swift ( ]In re Swift [) ],129 F.3d 792 , 795 (5th Cir. 1997) ; 5 COLLIER ON BANKRUPTCY 541.02 (15th ed. rev. 2005). Section 541's temporal limitation is the key to deciding this case.
Burgess v. Sikes (In re Burgess) ,
Thus, under current law, a debtor's interest in property may be contingent or enjoyment of the interest may be postponed until after bankruptcy, but the debtor must have had a prepetition legal interest nonetheless.
Second, Segal is distinguishable because the debtor did have a prepetition legal interest in that case...
Here, by contrast, Burgess suffered the crop loss before filing for bankruptcy, but he did not have a prepetition claim to, or interest in, the disaster-relief payment because the legislation authorizing the payment had not yet been enacted . If Burgess had no right or interest that constituted property within the meaning of 541(a)(1) at the commencement of the case, then the payment he later received cannot be proceeds of property of the estate under 541(a)(6).
...
In this case, at the time of filing, Burgess had only a mere hope that crop- disaster-relief legislation would be enacted *788. "This sort of nebulous possibility is not property ." [In re ] Schmitz , 270 F.3d [1254] at 1257 [ (9th Cir. 2001) ]. Were the law otherwise, any postpetition legislation or contract could retroactively create property of the estate. That cannot be the law; 541 clearly states that a bankruptcy estate is established at "the commencement of [the] case." Thus, Burgess had no interest, contingent or otherwise, in the disaster-relief payment when he filed his bankruptcy petition.
Mendelsohn is consistent with Burgess in light of the agreement of that trustee and Ross that no injuries existed prepetition, the agreement that the existence of a prepetition injury was a necessary element of there being any claim in existence as of the commencement of the case (not merely Ross not realizing that her medical problems were the prepetition injury caused by the Device), and the agreement that there was no prepetition claim for the Ross bankruptcy estate.
"Accrual" and the Delay of Discovery Doctrine
The parties have argued about, and become distracted by, the word "accrual" and the effect of the discovery rule on delaying "accrual," as well as any effect those may have on the running of the statute of limitations for a products liability claim. See Dckt. 75, 87, 94. Their arguments conflate the term "accrual," as it applies procedurally to when the statute of limitations runs, with whether Debtor has "acquired" rights that can be enforced against a third-party. As discussed below, California law provides for the tolling of the temporal limit (the statute of limitations) on when a person may file a complaint asserting rights against a third-party.
The Debtor's argument focuses on California Code of Civil Procedure § 312, dealing with the procedure for filing complaints and asserting rights, not the elements for, or the existence of, a claim against another person. California Code of Civil Procedure § 312 merely states that an action can be commenced only within the statutorily limited procedural time period after which a cause of action has "accrued" (not defining accrued), unless a statute provides that there is a different time notwithstanding the "accrual" of the claim. This rule does not address when a person has acquired rights or when all of the necessary elements exist for the person to have rights against another, but merely the timing for when that person may have access to the courts to try and enforce those rights.
In California, a cause of action (here asserted by the Trustee to be an interest included in the Bankruptcy Estate pursuant to
While California Code of Civil Procedure § 312 states that "[c]ivil actions, *789without exception, can only be commenced within the [statute of limitations], after the cause of action shall have accrued," there is an exception to the accrual rule for computing the statute of limitations, which exception is known as the "Delayed Discovery Rule." The Delayed Discovery Rule "postpones accrual of a cause of action until the plaintiff discovers, or has reason to discover, the [already existing] cause of action." Fox ,
For purposes of determining whether the statute of limitations has begun to run and the clock ticking down on the deadline for a complaint to be filed for a claim based on an existing right, the court looks at whether a plaintiff had "reason to at least suspect that a type of wrongdoing has injured [her]."
[a] potential plaintiff who suspects that an injury has been wrongfully caused must conduct a reasonable investigation of all potential causes of that injury. If such an investigation would have disclosed a factual basis for a cause of action, the statute of limitations begins to run on that cause of action when the investigation would have brought such information to light.
Id. at 808-09,
(1) the (procedural) statute of limitations begins running (accrues) from the time the rights came into existence; or
(2) the time period is tolled from the time the rights come into existence (acquired) and the running of the (procedural) statute of limitations is delayed.
This distinction between the claim and substantive rights coming into existence ("acquired"), and the "accrual" for the statute of limitations computation is noted in WITKIN, CALIFORNIA PROCEDURE , which states:
§ 432 Statute Affects Remedy Only.
(1) Statement of Principle. A statute of limitations is procedural ; it affects the remedy only, not the substantive right or obligation . (See Chase Sec. Corp. v. Donaldson (1945)325 U.S. 304 ,65 S.Ct. 1137 , 1143,89 L.Ed. 1628 , 1636, infra, § 460; Mitchell v. Automobile Owners Indem. Underwriters (1941) 19 C.2d [Cal.2d] 1, 4,118 P.2d 815 ; Mudd v. McColgan (1947) 30 C.2d [Cal.2d] 463, 467,183 P.2d 10 , infra, § 458; Piazza Properties, Ltd. v. Department of Motor Vehicles (1977) 71 C.A.3d [Cal.App.3d] 622, 628, 138 C.R. [Cal.Rptr.] 357, citing the text; Nelson v. Flintkote Co. (1985) 172 C.A.3d [Cal.App.3d] 727, 733, 218 C.R. [Cal.Rptr.] 562, citing the text;63 Harv. L. Rev. 1186 ;70 Harv. L. Rev. 1471 ;27 Hastings L. J. 1 [Interest Analysis and Conflicts Between Statutes of Limitation];94 A.L.R.3d 533 [whether running of statute of limitations on action is bar to arbitration of dispute]; 51 Am.Jur.2d (2000 ed.), Limitation of Actions §§ 22, 25 et seq.)
*7903 WITKIN, CALIFORNIA PROCEDURE 5TH ACTIONS § 432 (emphasis added).
The application of the Delayed Discovery Rule, and the delay of the "accrual" as that term is used in the California Code of Civil Procedure, does not determine whether the interest of the Debtor (the rights against the third-party) exist, just that the (procedural) statute of limitations would not begin to run until the Debtor and her Bankruptcy Estate knew of the pre-existing rights. The "accrual" does not destroy or constitute a novation of the rights subject to a condition subsequent. Neither party has directed the court to any statute which would delay Debtor having acquired the rights, only legal principles that the (procedural) statute of limitations would not begin to run under the Delayed Discovery Rule.
The Claims of Debtor and Class Action Settlement Proceeds Are Property of the Bankruptcy Estate
Contrasted to the debtor in Mendelsohn for which there was no prepetition injury, Debtor now before the court has claims and product liability rights not merely "rooted" in the prepetition period, but which germinated, sprouted, grew, blossomed, and became anchored prepetition. Debtor had, and the Bankruptcy Estate acquired, the products liability claim that existed prepetition.
The Bankruptcy Code requires only that the legal interest existed at the commencement of the case.
The court determines and shall issue a judgment (order form, Fed. R. Civ. P. 54(a), Fed. R. Bankr. P. 7054, 9014 ):
A. Determining that the claims and rights of the Debtor described on Amended Schedule B as "Mesh implant procedure personal injury claim" which form the basis for the Class Action Settlement and the Class Action Settlement Proceeds thereon are property of the Bankruptcy Estate in this case;
B. Holding that such determination that the claims, rights, and Class Action Settlement Proceeds are property of the Bankruptcy Estate in this case is without prejudice to Debtor's right to claim an exemption therein pursuant to11 U.S.C. § 522 (b) or the Trustee's right to file an objection or other action related thereto.
This Memorandum Opinion and Decision constitutes the court's findings of fact and conclusions of law. Fed. R. Civ. P. 52, and Fed. R. Bankr. P. 7052, 9014. The court shall issue a separate order consistent with this Decision.
Related
Cite This Page — Counsel Stack
586 B.R. 775, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-carroll-caeb-2018.